These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28423378)

  • 21. Current and emerging treatment strategies for cutaneous T-cell lymphoma.
    Lansigan F; Foss FM
    Drugs; 2010 Feb; 70(3):273-86. PubMed ID: 20166766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunoregulatory events in the skin of patients with cutaneous T-cell lymphoma.
    Hansen ER
    Arch Dermatol; 1996 May; 132(5):554-61. PubMed ID: 8624153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Staging and management of cutaneous T-cell lymphoma.
    Scarisbrick JJ
    Clin Exp Dermatol; 2006 Mar; 31(2):181-6. PubMed ID: 16487086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
    Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
    J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current therapy concepts in cutaneous T-cell lymphomas].
    Nestle FO; Häffner AC; Schmid MH; Dummer R; Burg G
    Schweiz Med Wochenschr; 1997 Feb; 127(8):311-20. PubMed ID: 9157537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on treatment of cutaneous T-cell lymphoma.
    Gardner JM; Evans KG; Musiek A; Rook AH; Kim EJ
    Curr Opin Oncol; 2009 Mar; 21(2):131-7. PubMed ID: 19532014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in understanding and managing cutaneous T-cell lymphomas.
    Brunner PM; Jonak C; Knobler R
    F1000Res; 2020; 9():. PubMed ID: 32419924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of hematopoietic stem-cell transplantation in cutaneous T-cell lymphoma.
    Hoff NP; Bruch-Gerharz D
    G Ital Dermatol Venereol; 2010 Jun; 145(3):345-59. PubMed ID: 20461043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Contribution of immunotherapy to the treatment of T-cell lymphoma of the skin].
    Bagot M; Boumsell L; Bensussan A
    Presse Med; 1999 Nov; 28(34):1911-6. PubMed ID: 10587730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
    Whittaker SJ; Foss FM
    Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
    Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
    J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver.
    Nicolay JP; Albrecht JD; Alberti-Violetti S; Berti E
    Eur J Immunol; 2021 Jul; 51(7):1660-1671. PubMed ID: 33811642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches.
    Foss F
    Leuk Lymphoma; 2003; 44 Suppl 3():S55-61. PubMed ID: 15202526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma.
    Schlapbach C; Ochsenbein A; Kaelin U; Hassan AS; Hunger RE; Yawalkar N
    J Am Acad Dermatol; 2010 Jun; 62(6):995-1004. PubMed ID: 20466174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma.
    Rook AH; Junkins-Hopkins JM; McGinnis KS; Wysocka M; Richardson SK; Budgin JB; Everitts S; Vittorio CC
    Adv Dermatol; 2002; 18():29-43. PubMed ID: 12528401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
    Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
    Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
    Vidulich KA; Talpur R; Bassett RL; Duvic M
    Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell signaling in cutaneous T-cell lymphoma microenvironment: promising targets for molecular-specific treatment.
    Rendón-Serna N; Correa-Londoño LA; Velásquez-Lopera MM; Bermudez-Muñoz M
    Int J Dermatol; 2021 Dec; 60(12):1462-1480. PubMed ID: 33835479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What Is New in Cutaneous T Cell Lymphoma?
    Morgenroth S; Roggo A; Pawlik L; Dummer R; Ramelyte E
    Curr Oncol Rep; 2023 Nov; 25(11):1397-1408. PubMed ID: 37874473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Malignant and Benign T Cells Constituting Cutaneous T-Cell Lymphoma.
    Nakai S; Kiyohara E; Watanabe R
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.